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A growing body of evidence suggests that the resistance of CLL cells to apoptosis is partly mediated through the
interactions between leukemia cells and adjacent stromal cells residing in the lymphatic tissue or bone marrow
microenvironment. Mcl-1, an anti-apoptotic protein that is associated with failure to treatment is up-regulated in
CLL lymphocytes after interaction with microenvironment. However, the regulation of its expression in context to
microenvironment is unclear. We evaluated and compared changes in Mcl-1 in CLL B-cells in suspension culture
and when co-cultured on stromal cells. The blockade of apoptosis in co-cultured CLL cells is associated with
diminution in caspase-3 and PARP cleavage and is not dependent on cytogenetic profile or prognostic factors of
the disease. Stroma-derived resistance to apoptosis is associated with a cascade of transcriptional events such as
increase in levels of total RNA Pol II and its phosphorylation at Ser2 and Ser5, increase in the rate of global RNA
synthesis, and amplification of Mcl-1 transcript levels. The latter is associated with increase in Mcl-1 protein level
without an impact on the levels of Bcl-2 and Bcl-xL. Post-translational modifications of protein kinases show
increased phosphorylation of Akt at Ser473, Erk at Thr202/Tyr204 and Gsk-3β at Ser9 and augmentation of total
Mcl-1 accumulation along with phosphorylation at Ser159/Thr163 sites. Collectively, stroma-induced apoptosis
resistance is mediated through signaling proteins that regulate transcriptional and translational expression and
post-translational modification of Mcl-1 in CLL cells in context to bone marrow stromal microenvironment.
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Chronic lymphocytic leukemia (CLL) is characterized by the gradual
accumulation of mature, non-proliferative B-cells. High levels of
anti-apoptotic protein Mcl-1 correlates with in vitro and in vivo
chemo-responses and poor clinical outcome [1]. Elevated Mcl-1 levels
prolonged the survival of CLL cells exposed to a variety of apoptosis-
inducing stimuli; down-regulation of Mcl-1 using antisense oligonucle-
otides resulted in a significant cell death. Other approaches to alter Mcl-1
expression or its anti-apoptotic function using small molecule BH3
mimetics [2], peptidomimetics [3] or cyclin dependent kinases [4]
predominantly sensitized CLL cells to programmed cell death. Together,
these observations underscore Mcl-1 as an important prognostic factor in
B-CLL pathogenesis.
A growing body of evidence suggests resistance of CLL cells to
apoptosis is partly mediated by the interactions between leukemia cells
and adjacent stromal cells residing in the lymphatic tissue or bonemarrow microenvironment. The target surface-receptors on B-cell such
as BCR (B-cell receptor) or CXCR4 are persistently activated by their
respective ligands (anti-IgM or CXCL12) expressed on the stromal cells
and or nurse like cells keeping the leukemia cells and stromal cells in
homeostasis [5,6]. This signaling event leads to the activation of BCR
Neoplasia Vol. 16, No. 12, 2014 Mcl-1 Regulation in CLL Microenvironment Balakrishnan et al. 1037signaling pathway, in which a number of downstream kinases are
activated that are essential for survival, homing and retention of CLL
cells [7]. In vitro studies using representative bone marrow stromal cells
demonstrated that CLL cells co-cultured on stromal cells induced
robust increase in anti-apoptotic proteinMcl-1, but not Bcl-2 or Bcl-xL
and associated withCLLB-cell survival [8–10].Other studies associated
with co-culturing of CLL primary cells with representative lymph node
microenvironment (with CD154-transduced system) demonstrated
increase in Bcl-xL and Bcl2-A1, which are other anti-apoptotic
members of Bcl-2 family proteins [11–13]. Activation of BCR pathway
in a ligand-dependentmanner significantly increased the levels ofMcl-1
in association with phosphorylation of Akt and Erk kinases [7].
Sustained activation of Akt, increased the level of pro-survival proteins
Mcl-1, Bcl-xL and XIAP and enhanced the leukemia cell survival;
however only down-regulation of Mcl-1, but not Bcl-xL or XIAP by
siRNA treatment induced apoptosis of CLL cells demonstrating the
direct association between Akt and Mcl-1 [6]. Spleen tyrosine kinase
(SYK) in a ligand-independent BCR signaling, demonstrated its
regulatory mechanism solely on Mcl-1 accumulation but not on XIAP
[14]. Close association between the ability of anti-IgM to induce BIM
phosphorylation and subsequent Mcl-1 release has been linked to
progressive disease [15]. Collectively, these studies reveal that the
proto-oncogenic role of Mcl-1 is not limited to sustained survival of
circulating CLL lymphocytes, but extended to BCR-mediated apoptotic
resistance in CLL. However, the mechanism or the molecular drive that
induces the Mcl-1 in the microenvironment niches is unclear.
The regulation of Mcl-1 is a complex phenomenon as it is known
to be regulated at different levels of transcriptional, translational and
post-translational modifications. Expression of Mcl-1 is regulated by
microRNAs miR15 and 16a, which are the negative regulators of
Mcl-1. Activated STAT3 is shown to bind in SIE related element in
the murine Mcl-1 promoter and increase Mcl-1 protein levels [16].
Mcl-1 is also a direct target of many transcription factors such as
NF-κB [17], cMYC [18], CREB [19], STAT-5 [20]. Studies have
previously revealed an increase in NF-κB [21] and MYC [22] when
malignant cells were co-cultured with BMSC. The association
between BCR protein kinases and Mcl-1 suggests that it is regulated
by Akt and Erk kinases. Using NK-Tert bone-marrow stromal cell
line we explore changes in key proteins in CLL lymphocytes. Our
data show that the induction of Mcl-1 in bone marrow stromal
microenvironment is associated with sequential events that include
activation of global transcription, translation and post-translational
(protein) modifications of signaling proteins.Figure 1. Comparison of expression of Bcl-2 family proteins in CLL
lymphocytes, normal lymphocytes and normal B cells. Protein
extracts obtained from CLL lymphocytes (n = 9) and normal
lymphocytes (n = 7) are loaded in equal amounts side by side in
the same gel and the levels of anti-apoptotic proteins (A) and pro-
apoptotic proteins (B) are evaluated by immunoblotting analysis.
GAPDH is used as a loading control. Normal B cells are isolated using
B-cell enrichment kit by negative selection. Immunoblots for Mcl-1,
Bcl-2, Bcl-xl and NOXA in isolated B cells (n = 5), normal PBMCSs
(n = 3) and CLL lymphocytes (n = 4) are provided (C).Patients and Methods
The present study is carried out in leukemic lymphocytes isolated
from peripheral blood samples obtained from patients with CLL as
described previously [8]. All patients signed written informed consent
forms in accordance with the Declaration of Helsinki and the
laboratory protocol approved by the Institutional Review Board at
The University of Texas MD Anderson Cancer Center.
Isolation of Normal Peripheral Blood Mononuclear Cells
(PBMC) and B-Cells (CD19 + ve Cells)
Whole blood is collected from healthy donors under an
institutional review board–approved protocol in heparinized tubes,
and lymphocytes are separated using ficoll gradient method [8]. The
isolated PBMCs are either used directly or subjected to B-cell
enrichment kit from STEMCELL Technologies (catalog #19054) topurify CD19 positive B-cells using negative selection. The purity of
B-cells is measured on the flow cytometer using CD19-APC antibody
(before and after isolation).
Preparation of CLL-MSC Co-Cultures
Whole blood from CLL patients is collected in heparinized tubes,
and lymphocytes are separated and cocultured with confluent layers
of human bone marrow stromal cells (NKtert; RIKEN Cell Bank,
Tsukuba, Japan) at a ratio of 100 CLL cells to 1 MSC or cultured
alone [8]. The cell lines are routinely tested for Mycoplasma infection
and authenticated by short tandem repeat analysis at MD Anderson
Cancer Center’s Characterized Cell Line Core facility [8].
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 40 41 42 43 44 45 77 78 79
0
25
50
75
100
P a t ie n t n u m b e r
%
 V
ia
bl
e 
ce
lls
 b
y 
Di
O
C 6
*Day 6
* * *
Con-24 hr NK-24 hr
0
25
50
75
100
cl
ea
ve
d 
ca
sp
as
e 
3,
 %
 c
on
tro
l
%
ap
op
to
sis
 o
f C
LL
 o
n 
NK
IGVH unmut IGVH mut
-10
0
10
20
30
%
 a
po
pt
os
is 
of
 C
LL
 o
n 
NK
ZAP70+ve ZAP70-ve
-10
0
10
20
30
A
B
C D E
Figure 2. BMSC confers cyto-protection but does not promote proliferation of CLL lymphocytes. A. CLL primary cells are co-cultured
either for 24 hours (samples 1 to 19 and 40 to 45) or until day 6 (samples 77 to 79) with or without bone marrow stromal cells (NKtert) in a
ratio of 100:1 and the viability of CLL lymphocytes are measured by DiOC6 method (grey bar, CLL cells in suspension; black bar, CLL cells
co-cultured on stroma). B. CLL primary cells are co-cultured for 24 hours with or without bone marrow stromal cells (NKtert). Protein
extracts are equally loaded and caspase 3 cleavage and PARP cleavage (n = 6) are analyzed by immunoblotting (C = CLL in suspension;
N = CLL on NKTert). GAPDH is used as a loading control. The percent viable cells for each sample are provided underneath the bands
C. The bands obtained for cleaved caspase-3 (19 kDa) is quantitated, normalized to GAPDH and graphed (n = 12). D–E. Stromal cel
mediated survival response on patients’ samples with different subset of CLL such as IGVH mutation and ZAP-70 status. D. Change in
percent apoptosis after 24 hours on BMSC is plotted against IgVH unmutated andmutated samples (n= 29). E. Change in percent viability
after 24 hours on BMSC in ZAP70-positive and -negative samples (n= 28). Twenty-two cases from Figure 1Awere analyzed for correlation
on percent viability of CLL cells with or without stroma (F). CLL primary cells from four patient samples are cultured in presence o
absence of BMSC support (NKTert cell line) for extended time (until day 6) and the end points with respect to cell viability (G) and
proliferation (H) are measured by annexin/PI and Ki-67 staining methods (n = 4). Left panels are quadrant plots of CLL cells cultured fo
6 days without stromal support, while right panels are the quadrant plots of CLL cells cultured for 6 days with stromal cells stained with
annexin and propidium iodide (G) or Ki-67 and propidium iodide (H).
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Figure 2 (continued).
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CLL cell viability is analyzed as described previously by standard
methods: annexin V/propidium iodide (PI) binding and 3,3-
dihexyloxocarbocyanine iodide (DiOC6) staining, based on the analysis
of mitochondrial transmembrane potential and cell membrane
permeability to PI [8].
Cell Proliferation Assay
Proliferation is measured using the Ki-67 staining method. Briefly,
after incubation, cells are washed with PBS and pelleted at 500 g for
5 min; the pellet is resuspended in 75% ethanol and left on ice. After30 min, the cells are washed twice and incubated with 20 μl Ki-67
antibody (FITC-conjugated anti-human Ki-67 from BD Biosciences)
and incubated in the dark for 30 min, washed with 1% BSA/PBS, added
to 10 μl propidium iodide (50 μg/ml), and analyzed immediately with a
FACSCALIBUR cytometer (Becton-Dickinson).Measurement of Global RNA Synthesis
Primary CLL cells in suspension or MSC co-culture are measured
for global RNA syntheses by [3H]uridine incorporation assay as
described previously [8].
1040 Mcl-1 Regulation in CLL Microenvironment Balakrishnan et al. Neoplasia Vol. 16, No. 12, 2014RNA Isolation and Real-Time Quantitative Polymerase
Chain Reaction
Total cellular RNA is extracted from CLL cells in suspension or in
co-cultures using Qiacube (QIAGEN, Valencia, CA). The RNAcontent and purity is measured byNanoDrop 1000 Spectrophotometer
(Thermo scientific Inc, Wilmington, DE). Total RNA (20–50 ng) is
used for the one-step real-time reverse-transcriptase polymerase chain
reaction (RT-PCR) in the TaqMan One-Step RT-PCR Master Mix
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in a 25-μl volume on 96-well optical reaction plate for 30 minutes at
48°C for reverse transcription reaction, followed by 10 minutes at 95°C
for initial denaturing, then followed by 40 cycles of 95°C for 15 seconds
and 60°C for 2 minutes in the 7900HT Sequence Detection System
(Applied Biosystems). The relative gene expression is analyzed by the
Comparative Ct method using 18s ribosomal RNA as endogenous
control, after confirming that the efficiencies of the target and the
endogenous control amplifications are approximately equal. All the
primers and probes (MCL-1, BCL-2, AKT, ERK) and reverse-
transcribed PCR buffers are purchased from Applied Biosystems, with
reference IDHS00172036_M1,HS00608023_M1,Hs00178289_m1,
Hs01052196_m1, respectively.
Immunoblot Analysis
CLL cell pellets are washed with PBS, lysed on ice in lysis buffer. After
protein content is measured using a DC protein assay kit (Bio-Rad
Laboratories), the samples are loaded, run and transferred to
nitrocellulose membranes (GE Osmonics Labstore) as described
previously [9]. Membranes are blocked for 1 hour in blocking buffer
and then incubated overnight at 4°C against the following: Akt,
phospho-Akt (Ser473), Erk, phospho-Erk, phospho-Gsk-3β (Ser9),
phospho-Mcl-1 (Ser159/Thr163) (Cell Signaling Technologies), or for
2 hours at room temperature for Rabbit polyclonal antibody to Mcl-1,
Bcl-XL and mouse monoclonal antibody to Bcl-2 (Santa Cruz, CA),
actin (Sigma, St. Louis, MO) and GAPDH (Abcam). The antibody to
poly (ADP-ribose) polymerase (PARP) is from BIOMOL International
(Plymouth Meeting, PA). Antibodies for total RNA pol II (8WG16)
and phosphorylated CTD at Ser2 (H5) or Ser5 (H14) are purchased
from Covance Research Products (Emeryville, CA). Total GSK-3β
antibody (BD biosciences), Bcl2A1 (Epitomics 1639-1), Bcl-xS (Santa
Cruz – sc-634, detects both Bcl-xL and xS), BAX (sc20067), BAK
(sc7973), BID (CST 2002), BIM (BD Biosciences) and PUMA (CST
4976) are used. After washing with PBS–Tween-20, membranes are
incubated with infrared-labeled secondary antibodies (LI-COR Inc) for
1 hour, scanned and visualized using LI-COROdyssey Infrared Imager.
Statistical Analysis
Linear regression analysis and Student t tests (two tailed) are performed
using Prism 6 software (GraphPad Software, Inc, San Diego, CA).Results
Expression of Bcl-2 Family Proteins in CLL Lymphocytes
Versus Normal PBMCs
Overexpression of Bcl-2 family anti-apoptotic proteins is commonly
associated with unfavorable prognosis in CLL. We compared theFigure 3.MSC-mediated activation ofRNAsynthesis, RNApol II protein
CLL lymphocytes (n=6) are incubated in presence (black bar) or absenc
RNA synthesis ismeasured by uridine incorporationmethod. The values
mean +/− SEM for the triplicate experiments from each patient sample
and total as well as phosphoRNA polymerase II are analyzed by immun
sites of the CTD ofRNA polymerase II. C. Total RNA polymerase II is n
are normalized to total pol II levels and the immunoblots are quantitated
presenceor absence ofMSC (NKTert cell line) for 24hours and levels of t
relative geneexpression is analyzedby the comparativeCtmethodusing
efficiencies of the target and the endogenous control amplifications
evaluation using two-tailed student paired t test.expression of Bcl-2 family pro-survival (Figure 1A) and pro-apoptotic
proteins (Figure 1B) between CLL lymphocytes (n = 9; freshly obtained
fromCLL patients) and normal PBMCs (n = 7; freshly obtained from age
matched healthy donors). The levels of BCL2-A1, Mcl-1, BCL-2 and
BCL-xL are relatively higher in CLL lymphocytes compared to normal
PBMCs. In regard to pro-apoptotic proteins, while BAK and t-BID
expression are comparatively higher in normal PBMCs, Bax levels are
similar in both sets of samples. Interestingly, BH3-only pro-apoptotic
proteins, BIM and PUMA are higher in CLL lymphocytes. Based on the
notion that anti- and pro-apoptotic proteins neutralize each other’s
function, one would speculate that there will be an inverse correlation
between anti-and pro-apoptotic protein levels in a given primary CLL
sample. In contrast, there is no such association observed between samples
suggesting that it is not the total protein; rather its function, regulation
and association with other proteins per se may play an important role in
disease progression. These data suggests that there is a differential
expression of Bcl-2 family proteins between CLL and normal PBMCs.
Given that PBMCs constitutes collection of other cells and CLL
cells are majorly B cells, we isolated CD19 + ve B cells from normal
PBMCs. The purity of CD19 + ve cells is tested by flow cytometer.
The cell extracts from normal B cells (n = 5), PBMCs (n = 3) and CLL
lymphocytes (n = 4) are run in parallel. Of note, the expression of
Mcl-1, Bcl-2 and Bcl-xl are similar in both normal B cells and CLL
cells (Figure 1C ).
BMSC Confers Cyto-Protection but Does not Promote
Proliferation in Quiescent CLL Lymphocytes
Others and we have shown previously that CLL cells co-cultured on
MSC enhance CLL survival [9]. Consistent to our previous reports,
co-culturing CLL cells on NKTert stromal cells (a human stromal cell
line that mimics the bone marrow stroma) increased the percent survival
of CLL cells (Figure 2A; 24 hour; n = 25; P b .0001). Extended
incubation of CLL cells on stromal cells until day 6 (Figure 2A; n = 3;
denoted by *), reachedN95%viability compared to 45, 58, 60% survival
in time-matched controls (P = .013). In concert with this data, 17 and
19 kDa cleaved caspase 3 fragments and 85 kDa cleaved PARP fragment
that are detected in CLL suspension cultures, significantly diminished in
co-cultured samples suggesting that the activation of caspases is reduced
by the stromal cells (Figure 2B; n = 6). Quantitation of immunoblots for
cleaved caspase-3 at 19 kDa showed a significant decrease in percent
cleavages in cells co-cultured on stroma (P b .0001; n = 12; Figure 2C ).
Data on caspase 8 and 9 demonstrated similar reduction in activation of
these upstream caspases (Supplemental Figure 1). A complete list of
patient samples (n = 45) and their clinical characteristics are provided in
Supplemental Table S1.
Therewas heterogeneity between samples replenishing on stroma; we
therefore investigated if there is any relevant association between patientlevel and phosphorylation andmRNA transcripts inCLL lymphocytes.
e (grey bar) of BMSC support (NKTert cell line) for 24 hours. A. Global
are presented as absolute DPM in 1*107 cells. The error bars denote
s. B. CLL primary cells (n= 6) are co-cultured on stroma for 24 hours
oblotting, using antibodies towards the phosphorylated Ser2 or Ser5
ormalized to GAPDH and phosphorylation at Ser2 and Ser5 of Pol II
and presented as dot plots. D. CLL lymphocytes are incubated in the
he indicated transcripts aremeasuredby real-timeRT-PCRassay. The
18s ribosomalRNAasendogenous control, after confirming that the
are approximately equal. The P value was determined by statistical
1042 Mcl-1 Regulation in CLL Microenvironment Balakrishnan et al. Neoplasia Vol. 16, No. 12, 2014prognostic markers and in vitro cell survival on MSC. The % apoptosis
against various prognostic markers is plotted. Number of prior therapies
or B2M levels demonstrated no association with percent viable cells on
MSC (data not shown). While apoptosis blockade in IgVH mutation
samples increased slightly compared to IgVH unmutated samples, it is
not statistically significant (Figure 2D; unmutated, n = 13, median
8.0% and mutated, n = 16, median 14.0%; P = .1962). Similarly, no
difference is observed between ZAP70 positive or negative samples
co-cultured on stroma (Figure 2E; ZAP70 + ve, n = 14, median 15%
and ZAP70 − ve, n = 14, median 13%; P = .5152). No association is
seen between percent spontaneous apoptosis and white blood cell count
in the peripheral blood (n = 45; data not shown). However, samples
with 17p deletion are comparatively resistant to spontaneous apoptosis
in culture (data not shown; n = 6). These data suggests that
MSC-mediated cyto-protection is independent of prognostic markers
and the disease stage.Of note, the increase in percent viability on stroma
demonstrated a liner relationship with percent viability with no stroma
in the same samples (Figure 2F; n = 22; r2 = 0.84, P b .0001).
Previously it was thought that the CLL B-cells are quiescent
cells and their accumulation was primarily associated with
resistance to apoptosis [23]. However, CLL is currently viewed
as a disease characterized by a dynamic balance between quiescent
cells circulating in the blood and proliferating cells located in
permissive niches in lymphoid organs. To test if MSCs modulate
the quiescent nature of CLL cells, lymphocytes co-cultured for
longer time on MSCs (up to 6 days) is measured for Ki-67
positivity. Longer incubations with MSCs extended the survival of
CLL lymphocytes (Figure 2G; day 6), with no indication of
replicating populations in the culture, suggesting that MSC does
not confer proliferation signals to CLL lymphocytes (Figure 2H;
day 6; n = 4).
MSC Co-Culturing Activate Total RNA Synthesis in
CLL Lymphocytes
CLL cells either cycling or quiescent, require active RNA
transcription for the continuous production of housekeeping and
other proteins needed for cell survival. Based on this notion, we
investigated if the changes in protein levels are indeed due to a
direct combinatorial effect of increased transcriptional machinery
or by means of indirect mechanisms. To test this, the effect of
incubation of CLL cells with NKtert stromal cells on [3H]uridine
incorporation is quantified. Data inferred that there is variability in
the basal levels of RNA synthesis among samples (grey bars) and
the macromolecule synthesis in response to BMSC is heteroge-
neous (black bars). Variability in the endogenous level of uridine
incorporation has been observed before [8,24]. Overall, the rates of
RNA synthesis increased significantly indicating that the sustained
survival of CLL cells in context to bone marrow microenvironment
is in part associated with an increase in global RNA synthesis
(Figure 3A, n = 6; P = .015).Activation of Global Transcription Associated With RNA
Polymerase II Activity in CLL Cells
Active transcription is dependent on enzyme RNA polymerase II
(pol II), as phosphorylation of its carboxyl terminal domain at Ser2
and Ser5 sites is essential for both transcriptional initiation and
elongation, respectively. To determine whether increase in rates of
RNA synthesis is in conjunction with activation of RNA pol II, the
total RNA pol II and the phosphorylation at Ser2 and Ser5 sites aredetermined. Primary samples co-cultured on stromal cells demon-
strated that while total RNA pol II levels remained similar under both
culture conditions, there is an increase in phospho RNA pol II at
Ser2 (n = 17; P = .007) and Ser5 (n = 17; P = .013) indicating that
CLL transcription machinery is activated in association with NK-Tert
cells (Figure 3, B and C ).
MSCs Promote the Amplification of mRNA Transcripts of
Pro-Survival Molecules in CLL Cells
As the degree of RNA synthesis is in close relationship with
percent cell survival, increase in RNA synthesis may be an important
biochemical mechanism in stromal-mediated survival of CLL cells.
The pro-active global RNA synthesis may eventually amplify
functional mRNA transcripts and subsequently increase protein
synthesis. Using RT-PCR technique we measured the mRNA
transcript levels of MCL-1, BCL-2, AKT and ERK kinases that are
important for survival of CLL cells. Transcripts for MCL-1, BCL-2,
AKT and ERK increased on stromal support (P = .006; P = .010; P =
.041; and P = .012, respectively); importantly, the greatest and
consistent increase in transcript levels is observed for MCL-1
(Figure 3D). Further analysis demonstrated a weak linear correlation
between Mcl-1 and BCL-2 (r2 = .4479; P = .0695) and strong
relationship with Erk and Akt (r2 = 1; P = .0001) transcript levels
(data not shown).
Post-Translational Modification of Pro-Survival Molecules in
CLL Cells on MSC
Given that cellular protein synthesis depends on functional mRNA
transcripts as the templates for translation, it is logical to speculate
that increase in RNA synthesis with respect to microenvironment may
lead to elevated protein synthesis. We compared the expression of
anti-apoptotic proteins (Mcl-1, Bcl-2 and Bcl-xL) in primary cells
co-cultured in presence or absence of stroma (Figure 4, A and B).
Among anti-apoptotic proteins,Mcl-1 (n = 48;P = .0006), but not Bcl-2
(n = 34; P = .46) and Bcl-xL expression (n = 16; P = .26; Figure 4B)
increased in co-cultured cells demonstrating a positive correlation
between transcription and translation of short-lived proteins. As PARP
cleavage is a direct measure of cell death, we correlated PARP cleavage
with Mcl-1 induction in presence of stroma (Figure 4, C andD; n = 8).
There is a very weak not-significant inverse correlation between these two
parameters (Figure 4D; n = 8; P = .314).
Expression of Protein Kinases in CLL Lymphocytes Versus
Normal PBMCs
In order to derive the significance of protein kinases in co-cultured
CLL lymphocytes, the expression of Akt and Erk in normal
lymphocytes, CLL lymphocytes and cells co-cultured on stroma
(Figure 5, A–D) are evaluated. Total Erk protein is similar in both
CLL and normal lymphocytes. While total Akt levels were
undetectable in normal PBMCs, but is expressed in CLL
lymphocytes; however, both Akt and Erk phosphorylation increased
in CLL cells co-cultured on MSC (Figure 5, B and C ). Quantitation
of immunoblots revealed statistical significance for pAkt (P = .04; n =
18) and Erk phosphorylation (P = .037; n = 6; Figure 5D).
GSK-3β is a substrate of Akt and Akt induces post-translational
modification of GSK-3β leading to loss of function, which otherwise
will phosphorylate its cognate substrate Mcl-1 at a conserved GSK-3
phosphorylation site (Ser159) promoting ubiquitination and degra-
dation of Mcl-1. Therefore, the levels of Gsk-3β protein in CLL
Mcl-1 Bcl-2 Bcl-xL
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Figure 4. MSC mediated changes in the expression of anti-apoptotic
proteins in CLL primary cells. A. CLL primary cells are co-cultured for
24 hours with or without bone marrow stromal cells (NKtert) in a ratio
of 100:1 and the protein extracts are equally loaded to detect the
anti-apoptotic proteins, Mcl-1, Bcl-2 and Bcl-xL (n = 8) using
respective antibodies by immunoblotting analysis (C = CLL in
suspension; N = CLL on NKTert). GAPDH is used as a loading
control. B. The immunoblots for Mcl-1 (n= 48), Bcl-2 (n= 34) and
Bcl-xl (n= 16) are quantified and normalized to the loading control
GAPDH. The P values are determined by statistical evaluation
using two-tailed student paired t-test. C and D. Correlation
between Mcl-1 and PARP cleavage was derived. C. Immunoblots
were performed forMcl-1 and PARP cleavage in the same samples
(n= 8). GAPDH is used as a loading control. D. Correlation between
Mcl-1 and PARP cleavage is derived using linear regression analysis
by Prizm software.
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Figure 5. MSC mediated changes in pro-survival kinases in CLL
primary cells. A. Protein extracts obtained from CLL lymphocytes
(n= 9) and normal lymphocytes (n= 7) are loaded in equal amounts
in the same gel and the protein levels of tAkt and tErk are evaluated
by immunoblotting analysis. B. CLL primary cells (n = 6) are
co-cultured for 24 hours with or without bone marrow stromal cells
(NKtert) in a ratio of 100:1 and the protein extracts are equally loaded
to detect tAkt and pAkt (Ser473) C. CLL primary cells (n = 6) are
co-cultured for 24 hours with or without bone marrow stromal cells
(NKtert) in a ratio of 100:1 and the protein extracts are equally loaded
to detect tErk and pErk by immunoblotting analysis (C = CLL in
suspension; N = CLL on NKTert). GAPDH is used as a loading
control. D. The phospho protein immunoblots (Akt and Erk) are
quantified and normalized to the total protein for cells on stroma,
graphed and compared with the cells in suspension cultures (100%
control) and plotted as dot plots.
Neoplasia Vol. 16, No. 12, 2014 Mcl-1 Regulation in CLL Microenvironment Balakrishnan et al. 1043lymphocytes, normal lymphocytes and cells co-cultured on stroma are
measured (Figure 6, A–C ). Total Gsk-3β is significantly higher in
CLL cells compared to normal lymphocytes (Figure 6A). Comparison
of total Gsk-3β protein and its phosphorylation status (at Ser9)
between CLL cells and cells co-cultured on stroma demonstrated that
pGsk-3β levels are significantly higher in cells co-cultured on stroma
(Figure 6, B and C; P = .0001; n = 18).
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Figure 6.MSCmediated changes in Gsk-3β in CLL primary cells. A.
Protein extracts obtained from CLL lymphocytes (n = 9) and
normal lymphocytes (n = 7) are loaded in equal amounts side by
side and the protein levels of tGSK and pGSK are evaluated by
immunoblotting analysis. B. CLL primary cells (n = 6) are co-
cultured for 24 hours with or without bone marrow stromal cells
(NKtert) in a ratio of 100:1 and the protein extracts are equally
loaded to detect tGsk-3β and pGsk-3β (Ser9). C. pGsk-3β
immunoblots is quantified and normalized to total protein and
plotted as dot plots. D. Mcl-1 phosphorylation at Ser159/Thr163 is
measured by immunoblotting analysis.
1044 Mcl-1 Regulation in CLL Microenvironment Balakrishnan et al. Neoplasia Vol. 16, No. 12, 2014There is a steady-state equilibrium between the production and
elimination of these molecules, the post-translational modifica-
tions of proteins (as reviewed previously [25]) may further stabilize
their expression and function. In conjunction to this hypothesis,
there is an increase in post-translational modification of protein
Mcl-1 at Ser159/Thr163 (Figure 6D) on co-cultured cells leading
to Mcl-1 stabilization.
Discussion
Mcl-1 protein is a vital component of survival pathway and its
regulation of expression and function are critical in cell survival
[1,10,26]. It has been previously shown that out of six members of
the Bcl-2 family anti-apoptotic proteins, Mcl-1 is up-regulated in
CLL cells in BMSC milieu [9,10], however the mechanism by which
it is regulated is not known. Given that DNA synthesis is not an
active episode in quiescent CLL, transcription is an essential processin CLL cells. In the same line, treatment with RNA directed agents
promoted cytotoxicity in CLL cells [27] and inhibition of mRNA
synthesis has been shown effective in killing CLL cells, suggesting that
transcription could be a principal target in quiescent cells [28]. Proof
of concept of this hypothesis was demonstrated by CDK7 and CDK9
inhibitors such as roscovitin, flavopiridol [4,29], and SNS-032
[30,31] that showed greater cytotoxicity towards CLL cells both in
pre-clinical models and clinical trials [31,32]. Importantly, the
mechanism by which CDK inhibitors induced cell death is through
the blockade of transcriptional events leading to a decline inmRNA and
protein levels of anti-apoptotic proteinMcl-1. As transcription is proven
a potential target in CLL, the resistance to apoptosis of CLL cells on
MSC is mediated through activation of transcriptional machinery
suggesting that the survival mechanisms promoted by MSCs is likely
dependent upon transcription that is regulated by both intrinsic
molecules and extrinsic signals derived from the microenvironment [8].
Mcl-1 is a protein that is inherently programmed for fast turn-over
[33] due to PEST sequences in the protein. However, Erk-mediated
phosphorylation of Thr163 in the PEST domain diminished the
degradation rate of Mcl-1 protein in Burkitt’s lymphoma B-cell line
[34]. Consistently, inhibition of Erk pathway by sorafenib is effective in
inducing apoptosis in primary CLL lymphocytes [35]. Post-translational
modifications of Mcl-1 protein at Ser121 residue leading to its
inactivation has been reported in HEK293, however this modification
is in response to stress [36]. Similarly, phosphorylation of Ser64 site of
Mcl-1 protein by CDKs has been demonstrated to be associated with
enhancement of anti-apoptotic property of the protein [37]. Addition-
ally, Mcl-1 protein is modified to undergo proteasomal degradation
after ubiquitylation by an E3 ligase, MULE [38]. Another novel E3
ligase that is selective for Mcl-1 is recently reported to regulate
degradation of this anti-apoptotic protein [39]. On the other hand,
degradation of Mcl-1 is also regulated by deubiquitination (DUB),
USP9X [40] a specific enzyme for Mcl-1 deubiquitination revealing
that stability of Mcl-1 is balanced through confined post-translational
modifications and concurrent proteasomal degradation pathways.
Gsk-3β (glycogen synthase kinase 3) controls Mcl-1 stability and
regulation of apoptosis [41]. Several kinases are known to mediate post
translational modification of Gsk-3β among which Akt is one of its
known kinases [42,43]. In presence of PI3K/Akt signaling axis, Akt
induces post-translational modification of Gsk-3β, which phosphory-
lates its cognate substrate Mcl-1 at a conserved GSK-3 phosphorylation
site (Ser159) promoting its ubiquitination and degradation. Thus,
Mcl-1 is a substrate of Gsk-3β and the expression ofMcl-1 is correlated
with pGsk-3β (Ser9) in multiple cancer cell lines and primary samples
[44,45]. Mechanistic studies have suggested that Akt mediated Gsk-3β
inactivation plays a role in Mcl-1 phosphorylation and stabilization
[26,46]. Activation of GSK-3β results in Mcl-1 degradation, while
inactivation ofGSK-3β causes accumulation ofMcl-1 promoting chemo-
resistance in a Mcl-1 dependent manner. In line, when CLL cells are
co-cultured on stroma, there is a consistent occurrence of increase in
phosphorylation of GSK-3β (glycogen synthase kinase 3; Figure 6) and
concurrent Mcl-1 accumulation. While rate of degradation was not
determined in our studies, Erk activation, phosphorylation of Mcl-1 at
Thr163 and concurrent accumulation of Mcl-1 are observed in
CLL-MSC co-cultures (Figures 5 and 6).
On the basis of these observations, we present a molecular model
(Figure 7) that illustrates the regulation of expression andmodifications of
Mcl-1 with respect to MSC. The stromal-mediated increase in RNA
synthesis could be due to activation of transcription factors such as c-MYC
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Figure 7.Molecular model of Mcl-1 regulation in CLL lymphocytes by bone marrow stromal microenvironment. Model representing the
regulation of Mcl-1 at various checkpoints such as transcriptional, translational and post-translational modifications in CLL cells with
respect to MSCs.
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production and subsequently elevates protein synthesis. Early response
genes such asMcl-1 are induced to a much greater extent than the RNA
transcripts with slow turnover rates. If the induction of short-lived
transcripts and proteins is thought to be a biochemical mechanism for
the survival of CLL cells, one would expect that direct inhibition of
transcription and translation by respective inhibitors may have a
cytotoxic effect on CLL cells; consistently, transcriptional and
translational inhibitors have demonstrated promising therapeutic
strategies for CLL [34,47,48].
Additionally, Mcl-1 is regulated by BCR signaling kinases such as
Akt, Erk and GSK. Phosphorylation of GSK-3β by Akt inactivates
GSK-3β and concurrent Mcl-1 degradation [41]. On the other hand,
Erk-mediated Mcl-1 phosphorylation at Thr163 in the PEST region
stabilizes this anti-apoptotic protein [34]. Harmonious with these
data, inhibition of PI3K delta by Cal-101 or SYK by R408 or Erk by
sorafenib resulted in malignant B-cell apoptosis in vitro [46] and
during therapy [49] in primary CLL cells [19,37,50].
In conclusion, the dynamic equilibrium between the stabilization
and degradation of Mcl-1 dictates the fate of a malignant cell. Because
Mcl-1 is a short-lived transcript and protein with high turnover rate
[51], any modulation with respect to cellular response would
significantly impact its alteration and expression. Our data
demonstrate a concerted effect on Mcl-1 in CLL cells influenced by
bone marrow microenvironment.Disclosure of Conflict of Interest
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